Search the Newsreel

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma has announced the activation of University Hospitals Cleveland Medical Center as the fourth clinical site for its STARLIGHT-1 Phase I/II clinical trial. This trial is evaluating EB103, an ARTEMIS® T-cell therapy targeting CD19, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. …

Estrella adds fourth site to EB103 lymphoma trial By Investing.com

Estrella Immunopharma Inc. (NASDAQ:ESLA) has activated a fourth clinical site, University Hospitals Cleveland Medical Center, for its STARLIGHT-1 Phase I/II trial of EB103. This trial evaluates EB103, a CD19-redirected T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The company anticipates using …

Estrella Immunopharma Inc (ESLA) Stock News Today

This article provides current stock information for Estrella Immunopharma Inc (ESLA), noting its recent price of $0.723 USD, a drop of 4.01%. It mentions that news and analysis, financials, stock score, technical forecast, ownership, dividends, and profile information are available, with more news expected …

Transindia Real Estate Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

TransIndia Real Estate Q1FY27 net profit rises 53%, led by other income surge

Kestrel Group Reports Second Quarter 2026 Financial Results

Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Estrella Immunopharma Inc (ESLA), detailing its current stock performance, market capitalization, and analyst ratings. It indicates a "Strong Buy" rating with a significant upside potential based on an updated analyst target price. The article also includes historical …

Price to book forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA

The article focuses on the "Price to book forward" metric for Estrella Immunopharma, Inc. (NASDAQ: ESLA), a health technology and biotechnology company. It presents a snapshot of the company's financial overview within the TradingView platform, noting that the market was closed at the time …

Estrella adds third site to EB103 lymphoma trial

Estrella Immunopharma Inc. has activated Oregon Health & Science University as the third clinical site for its STARLIGHT-1 Phase I/II trial of EB103. The trial evaluates EB103, a CD19-Redirected ARTEMIS T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. This expansion will …

Number of shareholders of Estrella Immunopharma, Inc. – NASDAQ:ESLAW

This article from TradingView is a placeholder or an incomplete data point regarding the number of shareholders for Estrella Immunopharma, Inc. (NASDAQ: ESLAW). It currently shows no specific shareholder data, indicating that the information is either unavailable or has not yet been populated for …

Kestrel Group Ltd. (KG) Q3 2024 Earnings: Loss Per Share of $0.16 as Shares Dip 0.35% - Management Guidance Update

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma announced the activation of Baylor Scott & White Research Institute as the second clinical site for its Phase I/II STARLIGHT-1 trial. This trial evaluates EB103, a CD19-Redirected ARTEMIS® T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). The expansion …

Estrella Immunopharma, Inc. Revenue Breakdown – NASDAQ:ESLAW

This article provides a basic overview of Estrella Immunopharma, Inc. (NASDAQ: ESLAW) financial information available on TradingView, focusing on its revenue breakdown. It indicates that further details regarding segment and regional performance by source and country can be accessed through the platform. The content …

Estrella activates second site for EB103 lymphoma trial By Investing.com

Estrella Immunopharma, Inc. has activated a second clinical site, Baylor Scott & White Research Institute, for its STARLIGHT-1 Phase I/II trial evaluating EB103 for relapsed or refractory B-cell non-Hodgkin’s lymphoma. This expansion aims to broaden the trial's reach and gather more data to determine …

Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Estrella Immunopharma Inc (ESLA), focusing on its PE, PB, and fair value. It includes current stock performance metrics and links to further financial data and company overviews.

Estrella Immunopharma Inc (ESLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Estrella Immunopharma Inc (ESLA). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page displays basic stock information such as market …

Estrella Immunopharma Inc (ESLA) Balance Sheet

This article provides detailed quarterly and annual balance sheet data for Estrella Immunopharma Inc (ESLA), allowing investors to analyze its financial health, liquidity, leverage, and return on equity. The balance sheet includes metrics such as cash and short-term investments, total assets, various liabilities, and …

Estrella Immunopharma Inc (ESLA) Cash Flow - Tradingkey.com

This article provides a detailed cash flow statement for Estrella Immunopharma Inc (ESLA), presenting quarterly and annual financial data for operating, investing, and financing activities. It includes key metrics like operating cash flow, net income, and changes in working capital, along with definitions for …

Estrella Immunopharma Inc (ESLA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Estrella Immunopharma Inc (ESLA), listing major individual and institutional holders. It specifies the proportion of shares held by different types of shareholders, including corporations, individual investors, and various investment firms. The report also includes historical institutional shareholding …

Kestrel Group, Ltd. Revenue Breakdown – NASDAQ:KG

TradingKey

This article provides a detailed income statement for Estrella Immunopharma Inc. (ESLA), presenting quarterly financial data for operating expenses, R&D expenses, operating profit, various net income metrics, and earnings per share. It also includes an overview of the company's stock performance and an FAQ …

Estrella Immunopharma Inc (ESLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Estrella Immunopharma Inc (ESLA), detailing its performance based on various indicators and moving averages. It covers MACD, RSI, KDJ, and other technical signals, indicating a "Neutral" overall signal. The analysis also explains what technical ratings and moving …

Estrella Immunopharma Inc (ESLA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Estrella Immunopharma Inc (ESLA), detailing various volatility and risk metrics. It covers maximum drawdown, return-to-drawdown ratio, skewness, realized volatility, and liquidity metrics such as average turnover rate. The data presented offers insights into the stock's historical performance …

Estrella Immunopharma Inc (ESLA) Institutional Confidence

This article from TradingKey provides an overview of Estrella Immunopharma Inc.'s (ESLA) institutional confidence. It lists key institutional shareholders, including Eureka Therapeutics Inc., Renaissance Technologies LLC, Geode Capital Management, L.L.C., and Citadel Advisors LLC, along with the number of shares held and the change …

Estrella doses first patient in EB103 trial expansion phase By Investing.com

Estrella Immunopharma Inc. (NASDAQ:ESLA) has announced that the first patient has been dosed in the expansion phase of its STARLIGHT-1 Phase I/II clinical trial for EB103, a CD19-redirected ARTEMIS T-cell therapy. This phase evaluates EB103 in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma, building on …

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma has dosed the first patient in the dose-expansion phase of its STARLIGHT-1 Phase I/II clinical trial for EB103, targeting relapsed/refractory B-cell non-Hodgkin's lymphoma. This milestone follows encouraging efficacy data from the dose-escalation cohort, where all patients who achieved complete response at 6 …

Estrella Immunopharma, Inc. (ESLA) stock price, news, quote and history

This page provides an overview of Estrella Immunopharma, Inc. (ESLA) stock, including its current price, after-hours trading, and historical performance. The article also features a news headline asking if the company is in a good position for growth. Performance metrics show significant negative returns …

Enterprise value to EBIT forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW

This article provides financial information for Estrella Immunopharma, Inc. (NASDAQ:ESLAW), focusing on its enterprise value to EBIT forward metric on TradingView. It highlights that the market was closed and no trades occurred, presenting an overview of the company's financial data.

Estrella Immunopharma Inc. (ESLA) Q2 2026 Earnings: Wider-than-Expected Loss Despite Double-Digit Stock Rally - Consensus Forecast Report

Transindia Real Estate completes acquisition of 48.28% stake in Comptech Solutions for ₹24 cr

Estrella Resources (ASX: ESR) Falls 11% as Manganese Explorer Consolidates

TransIndia Real Estate subsidiary AGSPL ceases to be wholly owned

ESLA Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue Biotech Development - EPS Guidance Update